Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.
about
Age-related inducibility of carboxylesterases by the antiepileptic agent phenobarbital and implications in drug metabolism and lipid accumulation.Paediatric drug development: are population models predictive of pharmacokinetics across paediatric populations?Pharmacokinetic research in children: an analysis of registered records of clinical trials.Injectable dexamethasone sodium phosphate administered orally? A pharmacokinetic analysis of a common emergency department practice.Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomicsScaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.Efficacy and Safety of a Lidocaine Gel in Patients from 6 Months up to 8 Years with Acute Painful Sites in the Oral Cavity: A Randomized, Placebo-Controlled, Double-Blind, Comparative Study.Federal legislation and the advancement of neonatal drug studiesQuantification of Flavin-containing Monooxygenases 1, 3, and 5 in Human Liver Microsomes by UPLC-MRM-Based Targeted Quantitative Proteomics and Its Application to the Study of Ontogeny.The influence of CYP2C8*3 on carbamazepine serum concentration in epileptic pediatric patients.Fluoxetine pharmacogenetics in child and adult populations.Specific safety and tolerability considerations in the use of anticonvulsant medications in children.Specific features of pharmacokinetics in children.Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age.Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.Population pharmacokinetics of intravenous bolus etomidate in children over 6 months of age.
P2860
Q33935727-2A48FCF3-FF35-4E93-A2DC-AD90D718357DQ35219662-973D8523-9524-465D-BC26-DAB9B26835CAQ35322451-0B702F31-F4EE-43A1-BC06-F2118425B3E9Q35566347-1350F511-674E-44FB-818A-B8AFC715186AQ35800807-0DEC52AF-BA85-4FE8-BA9B-D17DE584234FQ36336064-E38E618A-85E8-4DEE-AC61-960FD65FF762Q36366443-43C6A99D-AAD2-4AD1-8E4A-4F72A25A76D5Q37045447-DBC06CF6-65BF-4ABB-861B-6E8BDB8890A0Q37062604-69BC77EC-4A3F-4AD1-BD24-0C0F948D3D4FQ37262064-84C4E2BC-9123-4F37-A19F-4A4BA4D9517DQ38025986-3C242AB9-D024-420A-AF20-CF485BCEB2C4Q38026034-BE4AA9A7-8C10-4AB9-A0EA-ADC606CE9BA4Q38717340-BACFF050-365D-4ECB-ACAD-94A8608CDCFBQ39756044-896F697D-9FE9-490A-98D0-15C5C5F46DD4Q47548999-E21AED97-02C2-4228-82A2-FFB825A99604Q48231035-46E91A7B-3D74-4808-9063-0C637DA14F08
P2860
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.
@en
type
label
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.
@en
prefLabel
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children.
@en
P356
P1476
Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children
@en
P2093
Tsuyoshi Yokoi
P304
P356
10.2131/JTS.34.SP307
P478
34 Suppl 2
P577
2009-01-01T00:00:00Z